Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + Nivolumab +/- Ipilimumab in Relapsed/Refractory CD19+ Precursor B-ALL
NCT02879695Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab, nivolumab and ipilimumab in B cell acute lymphoblastic leukemia (B-ALL) and mixed phenotype acute leukemia (MPAL), sponsored by National Cancer Institute. Primary endpoints: Number of Participants Experiencing Grade 3, 4, or 5 Adverse Events at 5.5 years and Number of Participants With Dose Limiting Toxicities at 5.5 years. Started Oct 2017; status: active, not recruiting.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT02879695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879695.